ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.

Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implicated as a disease driver in a number of solid tumor...

全面介绍

书目详细资料

Principais autores:	Diego Alvarado, Gwenda F Ligon, Jay S Lillquist, Scott B Seibel, Gerald Wallweber, Veronique M Neumeister, David L Rimm, Gerald McMahon, Theresa M LaVallee
格式:	Artigo
语言:	Inglês
出版:	Public Library of Science (PLoS) 2017-01-01
丛编:	PLoS ONE
在线阅读:	https://doi.org/10.1371/journal.pone.0181356
标签:	添加标签 没有标签, 成为第一个标记此记录!